Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Rises By 103.0%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 121,000 shares, a growth of 103.0% from the December 15th total of 59,600 shares. Currently, 0.5% of the company’s stock are short sold. Based on an average daily volume of 153,600 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC boosted its holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the quarter. FMR LLC owned about 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent SEC filing. 86.70% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $3.50.

Bolt Biotherapeutics Stock Up 1.0 %

BOLT traded up $0.01 on Wednesday, hitting $0.52. 333,812 shares of the company were exchanged, compared to its average volume of 182,246. The firm has a 50-day moving average price of $0.57 and a two-hundred day moving average price of $0.64. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a twelve month low of $0.48 and a twelve month high of $1.56. The company has a market cap of $19.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.96.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.04). The firm had revenue of $1.14 million for the quarter, compared to analyst estimates of $1.02 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. On average, equities analysts predict that Bolt Biotherapeutics will post -1.61 earnings per share for the current year.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.